Treatment of relapsed/refractory multiple myeloma with weekly cyclophosphamide plus bortezomib plus prednisone or dexamethasone (CyBor-P/D): Updated experience at Princess Margaret Cancer Centre (PMCC)

Autor:	Young Trieu, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Donna E. Reece, Christine Chen, Giovanni Piza Rodriguez, Esther Masih-Khan
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty Cyclophosphamide Bortezomib business.industry medicine.disease Regimen Prednisone Internal medicine Cancer centre Immunology Relapsed refractory medicine business Dexamethasone Multiple myeloma medicine.drug
Zdroj:	Journal of Clinical Oncology. 32:e19568-e19568
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.e19568
Popis:	e19568 Background: We previously defined the efficacy of CyBor-P, a 28-day regimen consisting of cyclophosphamide 300 mg/m2 (days 1,8,15, 22), bortezomib 1.5 mg/m2 (days 1,8, 15) and prednisone 100...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1840259ed0d21a637133cbf9e46c0e74 https://doi.org/10.1200/jco.2014.32.15_suppl.e19568 Zobrazit plný text záznamu